Log in

Login to your account

Username *
Password *
Remember Me
Loading...
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Medicinal Chemistry Consultant for Drug Discovery, Preclinical Pharmacology and ADME

Technical Consultant #1513


Expertise

  • Pharmaceutical drug discovery process and implementation.
  • Drug discovery and medicinal chemistry.
  • Preclinical pharmacology, ADME (absorption, distribution, metabolism, and excretion of drugs) and pharmaceutical toxicology and safety.
  • Pharmaceutical drugs for anti-infectives, anti-virals, oncology and immunology.
  • Pharmaceutical drugs for cardiovascular and metabolic disease.
  • Pharmaceutical drugs for diabetes, obesity, aging and frailty.
  • Due diligence assessments, including intellectual property.

Experience

Undisclosed Company, President 2007 - Present

  • Drug discovery consultant with clients ranging from large to small pharmaceutical companies having portfolios in oncology, metabolic diseases, anti-virals, anti-bacterials and ocular diseases.
  • Consult on strategy and tactics in drug discovery including medicinal chemistry, preclinical pharmacology, ADME, pharmaceutics and drug safety.
  • Design and implementation of drug discovery programs and strategies to assure the expeditious achievement of drug discovery goals.

Undisclosed Company, 1981 - 2007

Executive Director Discovery, Chemistry, 2002 - 2007

  • Experienced across a wide array of peripheral and central target classes, including G-protein coupled receptors, nuclear hormone receptors, enzymes, exchangers, transporters, ion channels, and nucleoside analogs.
  • Responsible for all discovery chemistry programs in Metabolics Disease, placing 13 drug candidates into development with a team of 60 chemists.
  • Proactively worked to assure a sustainable pipeline of Metabolics Disease (diabetes/obesity) clinical candidates.
  • Regularly reviewed and creatively commented upon Metabolics Disease medicinal chemistry programs and actively participated in all discovery working group meetings.
  • Designated Medicinal Chemistry Division liaison to preclinical ADME, toxicology and pharmaceutics, helping establish processes to enable the timely identification of quality drug candidates.
  • Established priorities for the efficient application of ADME, toxicology and pharmaceutics resources to the Metabolics Disease program portfolio.
  • Routinely involved in the scientific assessment of potential external research collaborations and drug candidates.

Executive Director/Vice President Discovery Chemistry, 2001 - 2002

  • Responsible for all discovery chemistry programs at research site (Cardiovascular and Metabolics Disease), placing four compounds into development while leading a department of 100 chemists.
  • Regularly reviewed and creatively commented upon Metabolics Disease medicinal chemistry programs and actively participated in all discovery working group meetings.
  • Established priorities for the efficient application of ADME, toxicology and pharmaceutics resources.

Executive Director Discovery Chemistry, 1999 - 2001

  • Responsible for all discovery chemistry programs in cardiovascular disease, placing four compounds into development with a department of 50 chemists.

Executive Director Discovery Chemistry, 1998 - 1999

  • Responsible for all programs in Cardiovascular Disease and Immunology, placing four compounds into development.
  • Member of Joint Research Committee for Icagen collaboration.

Director Discovery Chemistry, 1993 - 1997

  • Responsible for several programs in virology, cardiovascular disease, oncology, and immunology.
  • Discovery team co-leader and first-inventor of entecavir (BaracludeTM), an orally active nucleoside analog with potent efficacy against human hepatitis B virus, currently marketed worldwide.
  • Led program identifying a lobucavir prodrug that significantly enhanced oral bioavailability.
  • Devised and helped implement a strategy to ensure exclusive access to bulk quantities of epothilones (oncology) by in-licensing proprietary know-how of fermentation processes.

Director and Associate Director Discovery Chemistry, 1989 - 1993

  • Responsible for antiviral chemistry efforts targeting herpesviruses, influenza and human immunodeficiency virus (nucleoside/nucleotide analogs, HIV protease, new leads).
  • Co-leader of the Ras farnesyl transferase program (oncology).

Group Leader Discovery Chemistry, 1986 - 1989

  • Responsible for antiviral chemistry programs.
  • Co-inventor of lobucavir (which entered Phase III), an orally bioavailable nucleoside analog with activity against herpes simplex virus, varicella-zoster virus, human cytomegalovirus, HIV and hepetitis B virus.
  • Co-led program leading to the identification of two additional nucleoside-analog development candidates for the treatment of herpes simplex and varicella-zoster virus infections, respectively.

Research Investigator and Group Leader, 1981 - 1986

  • Designed and synthesized novel beta-lactam antibiotics (monobactams).

Honors & Publications


Publications and Patents

  • Presenter and co-author of 38 presentations and posters.
  • Co-author of 52 papers
  • 32 patents

Education

  • Ph.D., University of California, Berkeley, CA
  • B.S., Chemistry, University of Tulsa, Tulsa OK
Back to Search Result GO